BJH - volume 8, issue Abstract Book BHS, february 2017
Q. Delefortrie , F. Lambert MD, G. Bulliard , M. Jurdan , S. Toffoli , D. Sartenaer , S. De Prophetis , D. Pranger MD, A. Kornreich MD, P. Mineur MD
BJH - volume 7, issue 5, october 2016
P. Mineur MD, C. Doyen MD, PhD, N. Straetmans MD, PhD, K. Van Eygen MD, D. Pranger MD, A. Bosly MD, PhD, M. André MD, T. Devos MD, PhD, L. Knoops MD, PhD, On behalf of the MPN Belgian Hematological Society subcommittee
This article describes the Belgian register of chronic myeloid leukaemia patients who have stopped their treatment with imatinib in conditions comparable to the French STIM trial results: 44% remained in major molecular response off therapy; relapses appear rapidly after stopping imatinib and are responsive when the treatment is resumed.
(BELG J HEMATOL 2016;7(5):184–6)
Read moreBJH - volume 7, issue Abstract Book BHS, january 2016
P. Vannuffel PhD, B. Cauwelier MD, PhD, P. Mineur MD, C. De Rop , D. Pranger MD, F. Nollet PhD
BJH - volume 7, issue Abstract Book BHS, january 2016
L. Knoops MD, PhD, G. Verhoef MD, PhD, Z. Berneman MD, PhD, D. Selleslag MD, N. Straetmans MD, PhD, L. Noens MD, PhD, P. Lewalle MD, PhD, M. André MD, D. Pranger MD, P. Zachée MD, PhD, E. Strobbe , L.J. McGarry , T. Devos MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
P. Mineur MD, C. Doyen MD, PhD, N. Straetmans MD, PhD, K. Van Eygen MD, D. Pranger MD, A. Bosly MD, PhD, M. André MD, T. Devos MD, PhD, L. Knoops MD, PhD
Top
